Cost-effectiveness of prophylactic antibiotic use to prevent catheter-associated urinary tract infections

被引:3
作者
Wang, Rui [1 ]
Hacker, Michele R. [1 ,2 ,3 ]
Lefevre, Roger [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Obstet, Gynecology, 330 Brookline Ave, Kirstein 3, Boston, MA 02215 USA
[2] Harvard Med Sch, Dept Obstet, Gynecology, Reprod Biol, Boston, MA 02115 USA
[3] Chan Sch Publ Hlth, Dept Epidmiol, Harvard T, Boston, MA 02115 USA
关键词
Costs and cost analysis; Cost-benefit analysis; Antibiotic prophylaxis; Urinary tract infections; Catheter-related infections;
D O I
10.1007/s00192-019-04034-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose We evaluate the cost-effectiveness of prophylactic antibiotic use to prevent catheter-associated urinary tract infections. Materials and methods A decision tree model was used to assess the cost-effectiveness of prophylactic antibiotics in preventing catheter-associated urinary tract infections for patients with a short-term indwelling urinary catheter. The model accounted for incidence of urinary tract infections with and without the use of prophylactic antibiotics, incidence of antibiotic-resistant urinary tract infections, as well as costs associated with diagnosis and treatment of urinary tract infections and antibiotic-resistant urinary tract infections. Costs were calculated from the health care system's perspective. We conducted one-way sensitivity analyses. Results The base case analysis showed that the use of prophylactic antibiotics is cost-saving in preventing catheter-associated urinary tract infections. The use of prophylactic antibiotics resulted in lower costs and higher quality-adjusted life-years compared with no prophylactic antibiotics. Sensitivity analyses showed that the optimal strategy changes to no prophylactic antibiotics when the incidence of urinary tract infections after prophylactic antibiotics exceeds 22% or the incidence of developing urinary tract infections without prophylactic antibiotics is less than 12%. Varying the costs of prophylactic antibiotics, urinary tract infection treatment, or antibiotic-resistant urinary tract infection treatment within a reasonable range did not change the optimal strategy. Conclusions Prophylactic antibiotic use to prevent catheter-associated urinary tract infections is cost-effective under most conditions. These results were sensitive to the likelihood of developing catheter-associated urinary tract infections with and without prophylactic antibiotics. Our results are limited to the cost-effectiveness perspective on this clinical practice.
引用
收藏
页码:285 / 289
页数:5
相关论文
共 15 条
  • [11] Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
    Neumann, Peter J.
    Cohen, Joshua T.
    Weinstein, Milton C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (09) : 796 - 797
  • [13] Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: Influence on the cost-effectiveness of different screening intervals
    Smith, Kenneth J.
    Cook, Robert L.
    Roberts, Mark S.
    [J]. VALUE IN HEALTH, 2007, 10 (05) : 358 - 366
  • [14] Costs and net health effects of contraceptive methods
    Sonnenberg, FA
    Burkman, RT
    Hagerty, CG
    Speroff, L
    Speroff, T
    [J]. CONTRACEPTION, 2004, 69 (06) : 447 - 459
  • [15] Catheter-associated urinary tract infections
    Warren, JW
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 17 (04) : 299 - 303